2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil

The STARTS-1 and -2 trials (Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension) and subsequent 2012 U.S. Food and Drug Administration (FDA) product labeling for sildenafil use in pediatric patients with pulmonary hypertension highlight many of the challe...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Circ Cardiovasc Qual Outcomes
Prif Awduron: Sable, Craig A., Ivy, D. Dunbar, Beekman, Robert H., Clayton-Jeter, Helene D., Jenkins, Kathy J., Mahle, William T., Morrow, William R., Murphy, Mary Dianne, Nelson, Robert M., Rosenthal, Geoffrey L., Stockbridge, Norman, Wessel, David L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5614492/
https://ncbi.nlm.nih.gov/pubmed/28663437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HCQ.0000000000000026
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg